BioNexus director reports no common stock holdings
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
BioNexus Gene Lab Corp reports initial insider holdings for director Yap Chee Keong. The disclosure lists a holding entry for common stock with 0.0000 shares owned directly as of the reported date, indicating no reportable direct equity position in the company’s common stock at that time.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Holding | COMMON STOCK | -- | -- | -- |
Key Figures
Key Terms
COMMON STOCK financial
direct_or_indirect regulatory
derivativeSummary financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does BioNexus Gene Lab (BGLC) director Yap Chee Keong report on this Form 3?
Does BioNexus Gene Lab (BGLC) director Yap Chee Keong report any insider transactions in this Form 3?
Is Yap Chee Keong identified as a director or officer of BioNexus Gene Lab (BGLC) in this Form 3?
Does the BioNexus Gene Lab (BGLC) Form 3 show any derivative securities for Yap Chee Keong?
AI-generated analysis. How Rhea-AI works. Not financial advice.